Last updated 14 July 2026
The lump was there for a few months, but it did not hurt, so it waited. The bleeding was put down to piles. The cough was blamed on the haze, then on the aircon, then on nothing in particular. Almost every late diagnosis begins with a perfectly sensible reason to wait a little longer, and almost none of them begin with anything that felt like an emergency.
That waiting is the thing worth understanding, because it is the difference between a cancer that can be removed and one that can only be managed. The Malaysia National Cancer Registry Report 2017-2021, published by the Ministry of Health, is blunt about where we stand: among cancers where a stage was recorded, nearly two thirds, 64.8 per cent, were already Stage 3 or Stage 4 by the time they were found. The registry is honest about its own limits, noting that a stage was documented for only about half of registered cases. Even so, the direction is not in doubt. Late does not mean hopeless. But it does mean harder, longer, costlier and more uncertain, and a great many of those diagnoses did not have to be late.
What “stage” really means
Staging describes how far a cancer has travelled by the time it is found. Stage 1 usually means a small tumour still sitting where it started. Stages 2 and 3 mean it has grown or reached nearby tissue and lymph nodes. Stage 4 means it has spread to distant organs. The stage at diagnosis is nobody’s fault, but it decides what treatment is even possible. A small, contained tumour can often be removed. A cancer that has scattered usually cannot be.
Which cancers Malaysians actually get
The registry counted 168,823 new cancer cases over those five years. Breast, colorectal and lung cancer lead the list, followed by lymphoma, liver, prostate, leukaemia, nasopharyngeal, uterine and ovarian cancers.
| Group | Most common cancers, in order |
|---|---|
| Malaysian women | Breast (by far the most common), then colorectal, then lung |
| Malaysian men | Colorectal, then lung, then prostate |
Source: Malaysia National Cancer Registry Report 2017-2021, Ministry of Health Malaysia.
This matters because three of these, breast, cervical and colorectal, have screening tests that genuinely work. Malaysia already offers all three.
What early detection actually buys you
“Early detection saves lives” is a slogan until you attach numbers to it. The Malaysian Study on Cancer Survival, published by the Ministry of Health in 2018, followed Malaysian patients for five years and showed how steeply the odds shift with stage.
| Stage at diagnosis | 5-year survival, breast cancer, Malaysia |
|---|---|
| Stage 1 | About 88% |
| Stage 2 | About 81% |
| Stage 3 | About 60% |
| Stage 4 | About 23% |
Source: Malaysian Study on Cancer Survival (MySCan), Ministry of Health Malaysia, 2018.
The distance between 88 per cent and 23 per cent is the whole argument for screening. The National Cancer Registry records that 50.5 per cent of Malaysian women with breast cancer are now found at Stage 3 or 4, up from 47.9 per cent in the previous registry period. We are catching our most treatable common cancer later than we used to.
Two honest caveats. Early detection improves the odds; it does not guarantee a cure. And the benefit is not equal across cancers: it works for cervical, colorectal and breast cancer, but for ovarian and pancreatic cancer no screening test is yet good enough to recommend.
The screening Malaysia actually offers
The Ministry of Health runs four national screening programmes, and only four. These are the current policies.
| Cancer | What is recommended in Malaysia |
|---|---|
| Cervical | HPV testing on a vaginal sample, either self-collected or taken by a health worker, for sexually active women aged 30 to 65. If negative, repeat in 5 years. |
| Breast | Clinical breast examination by a trained health professional. Yearly mammogram from age 40 for women with risk factors. For women aged 50 to 74, mammography every 2 years. |
| Colorectal | Immunochemical faecal occult blood test (iFOBT) for people aged 50 to 75 without symptoms, followed by colonoscopy if positive. |
| Oral | Oral examination from age 18 for people with high-risk habits, such as tobacco or betel quid chewing. |
Source: Ministry of Health Malaysia, National Strategic Plan for Cancer Control Programme 2021-2025.
The Ministry’s own Clinical Practice Guidelines on the Management of Breast Cancer add two things worth knowing. Screening mammography may be done every two years for women aged 50 to 74 in the general population, and offered from age 30 to women at high risk. And if you already have a breast symptom, the guideline sets a clock: you should be referred to a breast clinic within two weeks. That is a standard you are entitled to ask about.
The iFOBT is not glamorous: a small stool sample you collect at home, available at government clinics. It is how a polyp gets found and removed before it ever becomes cancer, and it is probably the least-used good test in the country. If cost or access is the obstacle, the National Cancer Society of Malaysia runs subsidised screening and patient support services, and is a reasonable first call if you do not know where to start.
For cervical cancer, Malaysia now uses HPV testing rather than the Pap smear alone, and offers self-sampling, so a woman can collect the sample herself instead of undergoing a speculum examination. Program ROSE, developed by researchers at Universiti Malaya with the Australian Centre for the Prevention of Cervical Cancer and now run by the ROSE Foundation, pioneered this here and operates across most states. For many women the real barrier was embarrassment, and self-sampling removes it.
Note what is absent. Malaysia has no national lung cancer screening programme. Low-dose CT scanning finds a great deal but also flags many harmless things, so it is considered only for people at high risk, such as heavy smokers.
The tumour marker myth
This is the most important section here, and it contradicts what many Malaysians are told.
A blood test for tumour markers cannot diagnose cancer, and it should not be used to screen healthy people for cancer. Tumour markers include CA-125, CEA, AFP and CA 19-9. They can be raised in someone who has cancer. They can also be entirely normal in someone who has cancer, and raised in someone who does not.
You do not have to take an overseas body’s word for this. Malaysia’s own guidance says it. The Ministry of Health’s Clinical Practice Guidelines on the Management of Colorectal Carcinoma state that the use of CEA is “exclusively confined for monitoring and follow-up” and that CEA “should not be used as a screening method”. A normal level does not mean you are free of bowel cancer. That is the entire logic of tumour markers in one line: they are for watching a cancer you already know about, not for finding one you do not.
CA-125 is the clearest example. It is often assumed to be an “ovarian cancer test”. Notice that ovarian cancer does not appear anywhere in Malaysia’s four national screening programmes, and there is a reason for that. The largest trial ever run on the idea, the UK Collaborative Trial of Ovarian Cancer Screening, randomly assigned more than 200,000 women to annual CA-125 testing, annual ultrasound, or no screening at all. After more than a decade of follow-up, published in The Lancet in 2021, neither screening approach reduced deaths from ovarian cancer. The false alarms, however, were real, and some women without cancer went on to have healthy ovaries removed.
The same caution applies to the liver. AFP is a tumour marker, not a diagnosis. Cancer is diagnosed by imaging and, in nearly all cases, by a biopsy. A blood result is a clue, never a verdict.
If a screening package promises to “detect cancer” from a blood draw, ask which cancer, on what evidence, and what happens if the result is abnormal.
Screening has downsides too
Good screening is not the same as more screening. Every test carries a cost that is not on the invoice.
- False positives. The test says something is wrong when nothing is, leading to more scans, more biopsies, weeks of fear, and sometimes procedures with real complications.
- False negatives. The test misses something. This is why a normal mammogram never cancels out a new lump. Symptoms always override an old clear result.
- Overdiagnosis. Some screen-detected cancers would never have grown fast enough to cause harm in a person’s lifetime, yet people are treated for them anyway.
- Whole-body scans. Sold as reassurance, they routinely find harmless lumps that then need investigating. There is no evidence they save lives.
Prostate cancer sits in the middle of this debate. The PSA test finds prostate cancer early, but many cancers it finds are slow-growing and would never have caused trouble, while treatment can cause incontinence and sexual dysfunction. Malaysia runs no national PSA programme, and the sensible route is a conversation with your doctor.
The tests with the strongest evidence, cervical HPV testing, the iFOBT and mammography in the right age groups, are precisely the ones Malaysians skip, while paying for tests never designed to screen anyone.
Symptoms that should not wait
Screening is for people with no symptoms. If you have symptoms, you do not need screening, you need a doctor. See one promptly for:
- A new lump anywhere, especially breast, armpit, neck or testicle. A painless lump is not more reassuring; it is often less.
- Blood in the stool, black or tarry stools, or a lasting change in bowel habit over several weeks.
- Bleeding between periods, after sex, or any bleeding after menopause.
- A cough that will not settle after three weeks, coughing up blood, or persistent hoarseness.
- Difficulty swallowing, persistent indigestion, or weight loss you did not intend.
- A mouth ulcer or patch that has not healed in three weeks.
- A blocked nose or blocked ear on one side, or a lump in the neck. These can signal nasopharyngeal cancer, which is comparatively common here.
- A mole that changes shape, colour or size, or a sore that will not heal.
Most of the time, these turn out not to be cancer. That is not a reason to wait. It is a reason to go and be told so.
Why Malaysians wait
If the tests are simple and available at government clinics, why is so much of our cancer found late? The reasons are human.
Fear of the answer. A Malaysian systematic review found “fear of the result” was the most commonly reported barrier to colorectal screening, cited by roughly a third of people. That fear is understandable, but it does the arithmetic backwards. Not knowing does not keep you at Stage 1. It moves you quietly towards Stage 4.
Assuming it is unaffordable. Money worries were the most frequent barrier to breast screening in the same review. Yet the iFOBT, clinical breast examination and cervical screening are available at government clinics at very low or no cost. And treating Stage 4 disease costs far more, in ringgit and in everything else, than treating Stage 1.
Trying traditional remedies first. This is common and rarely irrational; it is often a way of hoping while avoiding a frightening system. The problem is time. Cancer does not pause while a remedy is trialled for six months. If you use traditional approaches alongside medical care, tell your doctor, because some herbal products interact with cancer drugs.
Embarrassment. Being examined, collecting a stool sample, or having a speculum inserted feels undignified. That is exactly why HPV self-sampling and the home-collected iFOBT exist. The system has already bent to meet this concern.
Fatalism. The belief that cancer is a death sentence, so why look. The numbers say otherwise: nearly nine in ten women with Stage 1 breast cancer are alive five years later. Fatalism makes itself come true by keeping people away until it is late.
Seeing a doctor is not a commitment to bad news. It is how you find out that, most of the time, nothing is wrong. And if something is wrong, you have bought the most valuable thing in cancer treatment: time.
Lowering the risk in the first place
Screening finds cancer early. Prevention stops some of it from starting, and here Malaysia has a genuine success to point at. The country has vaccinated schoolgirls against HPV through a nationwide school-based programme since 2010, and the National Cancer Registry now records cervical cancer as one of the few cancers whose incidence in women is falling. That is what long-term prevention looks like when it works.
Beyond vaccination, much cancer risk is tied to tobacco, alcohol, excess weight, inactivity and diet. Carrying extra weight raises the risk of several cancers, including colorectal and post-menopausal breast cancer. The principles in our guide to foods that help prevent heart disease apply here almost unchanged: more vegetables, wholegrains and fibre, less processed and red meat, less sugar. If you live with diabetes, managing it well reduces more than just your heart risk. Beyond that: do not smoke, take up the HPV vaccine for eligible children, and ask about hepatitis B vaccination, since chronic hepatitis B is a leading cause of liver cancer here.
A short, practical checklist
- Woman aged 30 to 65: ask your clinic about HPV cervical screening, including self-sampling.
- Woman aged 40 and above: talk to your doctor about mammography and clinical breast examination.
- Anyone aged 50 to 75: ask a government clinic for an iFOBT kit. It takes minutes.
- Anyone with a persistent symptom above: do not wait for a screening appointment. Make a normal one.
- Anyone offered a “cancer blood test” or whole-body scan: ask what the evidence says it will change.
Two thirds is not a fact of nature. It is the sum of many decisions to wait a little longer, and every one of those can be made differently.
A note on this article. This is general health information, not personal medical advice. Everyone’s situation is different, and this article cannot account for your medical history, your medications, or your current condition. Always speak to your doctor or pharmacist before changing your diet, starting a supplement, or acting on anything you read here. If you are worried about your symptoms, contact your nearest clinic or hospital.
Guidelines and figures change over time. The information here reflects the sources available when this article was last updated, shown at the top of the page. Where a national guideline or registry is named, check the latest edition for the current position.